Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT.

Raj, KavitaEikema, Dirk-JanSheth, VipulKoster, Lindade Wreede, Liesbeth CBlaise, DidierDi Grazia, CarmelaKoc, YenerPotter, VictoriaChevallier, PatriceLopez-Corral, LuciaWu, DepeiMielke, StephanMaertens, JohanMeijer, EllenHuynh, AnnePassweg, JakobLuft, ThomasPérez-Simón, Jose AntonioCiceri, FabioPiekarska, AgnieszkaHayri Ozsan, GKröger, NicolausRobin, MarieYakoub-Agha, Ibrahim2023-05-032023-05-032022-09-28http://hdl.handle.net/10668/19519Myelodysplastic syndromes (MDS) are the second common indication for an Allo-HCT. We compared the outcomes of 1414 matched sibling (MSD) with 415 haplo-identical donors (HD) transplanted with post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis between 2014 and 2017. The median age at transplant with MSD was 58 and 61 years for HD. The median time to neutrophil engraftment was longer for HD being 20 vs 16 days for MSD (p enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/AdultCyclophosphamideGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansMiddle AgedMyelodysplastic SyndromesNeoplasmsRecurrenceRetrospective StudiesSiblingsTransplantation ConditioningUnrelated DonorsComparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT.research article36167679open access10.1038/s41408-022-00729-y2044-5385PMC9515068https://www.nature.com/articles/s41408-022-00729-y.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515068/pdf